-
Bolt Biotherapeutics Reveals Early Data From BDC-1001 Immuno-Oncology Candidate
Monday, December 6, 2021 - 9:38am | 279Read More...Bolt Biotherapeutics Inc (NASDAQ: BOLT) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker...
-
Gilead Wins Reversal of $1.2B Patent Loss to Bristol-Myers: Bloomberg
Thursday, August 26, 2021 - 12:58pm | 175Read More...Gilead Sciences Inc (NASDAQ: GILD) persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Squibb & Co (NYSE: BMY) had won over immuno-oncology treatments. The patent owned by Bristol-Myers’s Juno Therapeutics and the Sloan Kettering Institute for...
-
iBio Expands Immuno-Oncology Pipeline With RubrYc Deal
Wednesday, August 25, 2021 - 11:16am | 270Read More...iBio Inc (NYSE: IBIO) has signed an exclusive license agreement with RubrYc Therapeutics Inc for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs). Related: IBio Adds Three Cancer Antibody Programs. iBio plans to use its development and...
-
Affimed Shares Soar On $5B Collaboration With Roche's Genentech
Tuesday, August 28, 2018 - 10:12am | 370Read More...Affimed NV (NASDAQ: AFMD) shares are trading sharply higher Tuesday after the biopharma announced a collaboration agreement with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY)'s Genentech unit. Affimed shares were skyrocketing 148.7 percent to $3.98 at the time of publication...
-
Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug
Wednesday, August 22, 2018 - 10:50am | 356Read More...Shares of Netherlands-based biotech argenx SE – ADR (NASDAQ: ARGX) were trading up Wednesday following an announcement concerning its immuno-oncology antibody AGRX-115. What Happened Argenx said AbbVie Inc (NYSE: ABBV) has opted to exercise its exclusive option to license and...
-
Alkermes Initiates Phase 1 Clinical Trial Of Immuno-Oncology Drug Candidate ALKS 4230
Wednesday, May 25, 2016 - 11:47am | 338Read More...Alkermes Plc (NASDAQ: ALKS) revealed Wednesday that it initiated a phase 1 clinical trial of its immuno-oncology drug candidate, ALKS 4230, which was formerly referred to as RDB 1450, a novel Selective Effector Cell Activator protein designed for targeted interleukin-2 (IL-2) receptor activation....
-
Agenus Shares Spike Higher Following Mid-Day Upgrade To Buy From Maxim
Saturday, March 12, 2016 - 1:04pm | 408Read More...Shares of Agenus Inc (NASDAQ: AGEN) were trading up more than 9 percent on Friday afternoon, after Maxim Group upgraded its rating on the stock from Hold to Buy, while establishing a price target of $7.00. Analysts Jason McCarthy and Jason Kolbert highlighted a few elements behind their...
-
Bristol-Myers Looks To A Promising Future
Wednesday, February 17, 2016 - 9:17am | 358Read More...Pharmaceutical company Bristol-Myers Squibb Co (NYSE: BMY) has some big opportunities on the horizon, and analysts are taking notice. At a time when many pharma companies are beginning to worry about political battles over lowering drug prices, Bristol-Myers Squibb is hoping its bright future will...
-
Galena Biopharma 2016 Outlook Focuses On 'High Value' Cancer Immunotherapy Pipeline
Wednesday, January 13, 2016 - 2:37pm | 263Read More...Shares of Galena Biopharma Inc (NASDAQ: GALE) were trading lower by more than 5 percent at $0.770 on Wednesday after the company detailed its 2016 strategy. Galena Biopharma noted that its 2016 strategy to advance the company's "high value" cancer immunotherapy clinical...
-
Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says
Tuesday, April 21, 2015 - 12:57pm | 346Read More...In a report published Tuesday, RBC Capital Markets analyst Michael Yee commented on the increasing Street "appreciation" over the idea that Gilead Sciences, Inc. (NASDAQ: GILD) should acquire Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Yee noted that many investors are working...
